BiomeSense is developing a fully automated biosensor for low-cost, scalable microbiome testing. The device will solve the cost and patient adherence problems with current testing methods, making longitudinal sampling routine. This will exponentially improve the data available to researchers, accelerating the microbiome’s integration into therapeutic development, clinical practice, and more. BiomeSense is based on research from Jack Gilbert, a professor in the department of surgery at the University of Chicago Medicine and the faculty director of the University’s Microbiome Center, and Savas Tay, an associate professor at the Institute of Molecular Engineering. The team also includes Kevin Honaker, a recent graduate of the University of Chicago Booth School of Business. The company was awarded up to $250,000 at the Spring 2018 George Shultz Innovation Fund Finals.
- Founded by Kevin Honaker, Jack Gilbert, PhD, and Savas Tay, PhD
- Awarded up to $250,000 at the Spring 2018 George Shultz Innovation Fund Finals
- Headquartered in Chicago, IL